Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

Jayne, David; H. Rovin, Brad; Mysler, Eduardo; Furie, Richard; Houssiau, Frédéric; Trasieva, Teodora; Knagenhjelm, J.; Schwetje, Erik; Lin Chia, Yen; Tummala, Raj; Lindholm, Catharina

doi:10.1136/annrheumdis-2021-221478

Public

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

Published in Annals of the Rheumatic Diseases • Feb 10, 2022

Authors:

David Jayne

Brad H. Rovin

Eduardo Mysler

Abstract

OBJECTIVE: To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. METHODS: This phase II double-blinded study randomised 147 patients (1:1:1) to receive monthly intravenous anifrolumab basic reg...

Subject

Medicine

Lupus nephritis

Systemic lupus erythematosus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!